Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks Flexibility For Genetic Test Review Template, But Not Too Much

This article was originally published in The Gray Sheet

Executive Summary

FDA and members of the Secretary's Advisory Committee on Genetic Testing are developing guidelines that explain how to fill in a proposed FDA data template for genetic tests.
Advertisement

Related Content

IVAT Proposal Drafters Consider Alternatives, Faced With FDA Reservations
IVAT Proposal Drafters Consider Alternatives, Faced With FDA Reservations
Genetic Tests: SACGT Asks FDA To Fill In Details Of Premarket Process
Genetic Tests: SACGT Asks FDA To Fill In Details Of Premarket Process
FDAMA Allows Novel Genetic Tests To Be Regulated As 510(k)s - CDRH
FDAMA Allows Novel Genetic Tests To Be Regulated As 510(k)s - CDRH
Advertisement
UsernamePublicRestriction

Register

MT014861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel